The Dermatology Digest
FEBRUARY 5, 2025
We are pleased to announce our non-exclusive partnership with LEO Pharma, which has demonstrated a strong track record in developing medicines for hard-to-treat skin conditions, saysProf.Hubert Truebel, MD, MBA, Managing Director at DEBRA Research, in a news release. There are currently no approved treatment options for EB.
The Dermatology Digest
MARCH 14, 2025
Novartis is the official first-in-category corporate pharmaceutical partner of the National Football League (NFL). The partnership aims to empower football fans everywhere to make proactive decisions about their health, better understand screening guidelines and create a playbook for a healthier future.
The Dermatology Digest
APRIL 3, 2024
Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Pelthos is a wholly owned subsidiary of Ligand.
The Dermatology Digest
JUNE 13, 2024
Mr. Høiland has more than 25 years of experience in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US). He will succeed Tord Lendau. “He will bring valuable insights and experience especially from the US market, which is our primary focus.
The Dermatology Digest
JULY 22, 2024
Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. This launch symbolizes the robustness of our platform, the value of our partnership with STADA, and our collective focus on the importance of biosimilars.”
The Dermatology Digest
JANUARY 4, 2024
Joint development for DMB-3115 was initiated in 2013 by Dong-A Socio Holdings and Meiji Seika Pharma, with exclusive commercialization rights granted to Intas Pharmaceuticals through a partnership announced in 2021. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for U.S. commercialization.
The Dermatology Digest
FEBRUARY 27, 2024
This approval marks an important milestone for Teva and Alvotech’s partnership to collaborate on seven biosimilars and expand the availability, access, and uptake of biosimilars in the U.S.” where biologics represent well over 40% of all pharmaceutical spending.
Expert insights. Personalized for you.
65 
Let's personalize your content